Signaling of Serum Amyloid A Through Receptor for Advanced Glycation End Products as a Possible Mechanism for Uremia-Related Atherosclerosis | Zendy

Karim Belmokhtar | Zendy; Thomas Robert | Zendy; Jérémy Ortillon | Zendy; Antoine Braconnier | Zendy; Vincent Vuiblet | Zendy; Camille BoulagRombi | Zendy; Marie Danièle Diebold | Zendy; Christine Piètrement | Zendy; Ann Marie Schmidt | Zendy; Philippe Rieu | Zendy; Fatouma Touré | Zendy

Open Access

Signaling of Serum Amyloid A Through Receptor for Advanced Glycation End Products as a Possible Mechanism for Uremia-Related Atherosclerosis

Author(s) -

Karim Belmokhtar,

Thomas Robert,

Jérémy Ortillon,

Antoine Braconnier,

Vincent Vuiblet,

Camille BoulagRombi,

Marie Danièle Diebold,

Christine Piètrement,

Ann Marie Schmidt,

Philippe Rieu,

Fatouma Touré

Publication year - 2016

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.115.306349

Subject(s) - glycation , uremia , mechanism (biology) , amyloid (mycology) , receptor , advanced glycation end product , medicine , chemistry , endocrinology , pathology , philosophy , epistemology

Cardiovascular disease is the leading cause of death in patients with end-stage renal disease. Serum amyloid A (SAA) is an acute phase protein and a binding partner for the multiligand receptor for advanced glycation end products (RAGE). We investigated the role of the interaction between SAA and RAGE in uremia-related atherogenesis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research